Head-to-head evidence
ERX1000 vs metreleptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Leptin · full Obesity pipeline
ERX1000
Developed by ERX Pharmaceuticals
NCT04890873 · Phase 1 · completed
Participants were randomized to ERX1000 or a matching placebo with blinding of both participants and investigators, but the primary endpoints reported are safety measures (adverse events, laboratory, ECG, vital-sign, and exam abnormalities) rather than weight or metabolic efficacy, and no results have been posted.
Next expected readout: May 2027 · NCT07570758 (registry estimate)
metreleptin · Myalept
Marketed by Chiesi Farmaceutici
NCT01155180 · Phase 2 · completed
The trial was randomized, double-blind, and placebo-controlled, but it included only 24 participants (18 leptin and 6 placebo), making it small for a controlled comparison. Its clinical primary endpoint was not accompanied by a reported p-value or confidence interval, so whether the treatment comparison was statistically significant is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ERX1000's landscape · metreleptin's landscape